A new drug to treat age related macula degeneration will be Fovista. This drug will be combined with existing anti-VEGF drugs such as Eyela, Avastin or Lucentis and it will make the vision of patients suffering from this serious disease even better. It will also be administered in form of ocular injections at monthly intervals together with the aforementioned drugs. While the function of anti-VEGF drugs (Eyle, Lucentis and Avastin) is mainly to prevent bleeding and swelling in the macula, the function of Fovista is to prevent scarring.

Currently around the world a large multicenter study is as its last stages before the approval of Fovista and before its marketing. Its non-toxicity and usefulness has already been demonstrated. The Clinic Svjetlost participates in this American study because it met the high technical and technological criteria required. Patients with wet macular degeneration, which have not received injections of anti-VEGF as yet should report to our clinic and may be included in the study and receive free anti-VEGF drugs in combination with Fovista. Inclusion in the study lasts until autumn 2016.